Clinical TopicsHome Page Recent ArticlesNeurologyNews

Emerging treatment for early Alzheimer’s disease

By: Lydia L. Kim, Digital Content Editor

Biogen announced that it will pursue the U.S. Food and Drug Administration (FDA)’s regulatory approval process for its drug aducanumab to treat Alzheimer’s disease.

The decision was based on findings from the phase 4 EMERGE study, which met its primary endpoint in revealing a “significant reduction in clinical decline.” If aducanumab is approved, it will become the first treatment to demonstrate that removing amyloid beta may lead to better clinical outcomes.

Beta-amyloid is connected to Alzheimer’s based on its makeup and the fact that it can accumulate and create amyloid plaques, one of the hallmark features of a brain in patients with Alzheimer’s disease.

The Alzheimer’s Association has previously released an FAQ on beta-amyloid, which can be found here, and may be a useful resource for patients and healthcare providers.

The potential approval for aducanumab may be a pivotal option for patients with Alzheimer’s disease, and a development American Nurse Today plans to track.

Please read the entire press release here.


The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


More Perspectives